Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program

BACKGROUND: The global EINSTEIN DVT and PE studies compared rivaroxaban (15 mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K antagonist therapy and demonstrated non-inferiority for efficacy and superiority for major bleeding. Owing to differences in targeted anticoa...

Full description

Saved in:
Bibliographic Details
Published in:Thromb J
Main Authors: Yamada, Norikazu, Hirayama, Atsushi, Maeda, Hideaki, Sakagami, Satoru, Shikata, Hiroo, Prins, Martin H, Lensing, Anthonie WA, Kato, Masaharu, Onuma, Junichi, Miyamoto, Yuki, Iekushi, Kazuma, Kajikawa, Mariko
Format: Artigo
Language:Inglês
Published: BioMed Central 2015
Subjects:
Original Clinical Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4339301/
https://ncbi.nlm.nih.gov/pubmed/25717286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-015-0035-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items